###### **Endnotes**

1 Adams, M.P.; Josephson, D.L.; Holland, L.N. (2005). Pharmacology for Nurses, A Pathophysiologic Approach*.* Upper Saddle River, NJ: Pearson Education, Inc.

2 Lehne, R.A. (2001) Pharmacology for Nursing Care, 4th ed*.*, Philadelphia: W.B. Saunders Company.

3 Ibid.

4 Ibid.

5 Villines, TC et al. “Niacin: the evidence, clinical use, and future directions.” *Curr Atheroscler Rep*: 2012 Feb; 14(1): 49-59. Accessed December 18, 2013: http://www.ncbi.nlm.nih.gov/pubmed/22037771.

6 Klabunde, PhD, R.E. Cardiovascular Pharmacology Concepts. Accessed September 4, 2011: http://www.cvpharmacology.com.

7 van der Hoogt, C.C. et al. “Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.” *Journal of Lipid Research*, Volume 48, Issue 8, pp 1763-1771. Aug 2007. Web. 5 October 2011.

8 Wang XY, et al. Emerging antivirals for treatment of hepatitis B. World Journal of Gastroenterology. 2014;20:1777.

9 Ibid.

10 Ibid.

11 World Health Organization: The top 10 causes of death (2011). Updated July 2013. Accessed December 18, 2013: http://www.who.int/mediacentre/factsheets/fs310/en/index.html.

12 Bankhead, C. (2008) *Raloxifene (Evista) Reduces Risk of ER-Positive Invasive Breast Cancer.* Breastcancer.org. Accessed March 7, 2012: http://www.breastcancer.org/treatment/chemotherapy/new\_research/20080611.jsp.

13 Lehne, R.A. (2001) Pharmacology for Nursing Care, 4th ed*.*, Philadelphia: W.B. Saunders Company.

14 Reneric, JP; Lucki, I (1998). “Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rate forced swimming test”. *Psychopharmacology*: 136: (2): 190-7.

15 Lehne, R.A. (2001) Pharmacology for Nursing Care, 4th ed*.*, Philadelphia: W.B. Saunders Company.

16 Muller-Oerlinghausen, B; Berghofer, A, Ahrens, B (2003). “The Antisuicidal and Mortality-Reducing Effect of Lithium Prophylaxis: Consequences for Guidelines in Clinical Psychiatry”. *Canadian Journal of Psychiatry*. 48 (7): 433-9.

17 Antitussives (2000-2012). Drugs.com. Accessed Mar 11, 2012: http://www.drugs.com/drug-class/antitussives.html.

18 COPD Health Center (2010). “Anticholinergics for Chronic Obstructive Pulmonary Disease (COPD).” WebMD.com. Accessed Mar 11, 2012: http://www.webmd.com/lung/copd/anticholinergics-for-chronic-obstructive-pulmonary-disease-copd.

19 Lehne, Richard A. Pharmacology for Nursing Care, 4th ed*.*, Philadelphia: W.B. Saunders Company, 2001.

20 Adams, M.P.; Josephson, D.L.; Holland, L.N. (2005). Pharmacology for Nurses, A Pathophysiologic Approach*.* Upper Saddle River, NJ: Pearson Education, Inc.

21 Mayo Foundation for Education and Research (2011). “Red yeast rice (Monascus purpureus)”. Mayo Clinic Drugs and Supplements. Accessed Mar 11, 2012: http://www.mayoclinic.com/health/red-yeast-rice/NS\_patient-redyeast.

22 Kogan, N (2007). “Cannabinoids in health and disease.” Clinical Neuroscience: 2007 Dec; 9(4): 413-430. Accessed Dec 20, 2013: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202504/>.

23 [Governing.com](file:///C:\Users\joymil\AppData\Local\Microsoft\Windows\INetCache\Content.Outlook\DED1T24Y\Governing.com). “State Marijuana Laws in 2018 Map”. Accessed Nov 27, 2018. http://www.governing.com/gov-data/safety-justice/state-marijuana-laws-map-medical-recreational.html

24 Health Canada. “Where Does the Government of Canada Stand on the Issue of Medical Use of Marihuana?” *Frequently Asked Questions*. Accessed Dec 31, 2013: <http://www.hc-sc.gc.ca/dhp-mps/marihuana/about-apropos/faq-eng.php>.

25 O’Malley, Dennis. “Medical marijuana users will pay their own way.” *CT Post*. Dec 30, 2013. Accessed Dec 31, 2013: <http://www.ctpost.com/local/article/Medical-marijuana-users-will-pay-their-own-way-5100869.php>.

26 Southwest Medical Marijuana Evaluation Center (2011). “Methods of Medicating with Marijuana.” Accessed Dec 31, 2013: <http://www.evaluationtoday.com/news_medicating_with_marijuana.html>.

27 Hecht, Peter (2012). “California pot research backs therapeutic claims.” The Sacramento Bee: 2012-07-12T17:27-59Z. Accessed Mar 28, 2013: <http://www.sacbee.com/2012/07/12/4625608/california-pot-research-backs.html>.

28 Lynch, ME and Campbell, F (2011). *Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.* British Journal of Clinical Pharmacology: 2011 Nov;72(5):735-44. Accessed Dec 20, 2013: <http://www.ncbi.nlm.nih.gov/pubmed/21426373>.

29 Carter, GT et al (2011). *Cannabis in palliative medicine: improving care and reducing opioid-related morbidity.* American Journal of Hospital Palliative Care: 2011 Aug:28(5): 297-303. Accessed Dec 20, 2013: <http://www.ncbi.nlm.nih.gov/pubmed/21444324>.

30 Sirven, J (2013). “On Epilepsy and Marijuana”. Epilepsy.com, originally published Sep 15, 2011; Revised Sep 2013. Accessed Jan 6, 2014: <http://www.epilepsy.com/epilepsy/medical-marijuana>.

31 Russo, E (2013). *Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential*. Routledge. P 191. ISBN 978-1-136-61493-4. Accessed Dec 21, 2013: <http://books.google.com/books?id=qH-2Lj9x7L4C&pg=PT191#v=onepage&q&f=false>.

32 Ferner, M (2013). “Weed Pioneers Look to Save Epileptic Kids With New Medical Marijuana Strain”. *The Huffington Post*: Nov 13, 2013. Accessed Dec 10, 2013: <http://www.huffingtonpost.com/2013/11/13/charlottes-web-marijuana_n_4261935.html>.

33 Colasanti B, et al (1982). “Effects of marijuana cannabinoids on seizure activity in cobalt-epileptic rats” *Pharmacology Biochemistry and Behavior*. 1982 Apr;16(4): 573-578. Accessed Dec 14, 2013: http://www.sciencedirect.com/science/article/pii/009130578290418X.

34 Kogan, M, Mechoulam, R (2007). “”Cannabinoids in health and disease”. *Dialogues in Clinical Neuroscience*. 2007 Dec; 9(4): 413-430. Accessed Dec 10, 2013: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202504/.

35 Di Carlo G, Izzo AA (2003). “Cannabinoids for gastrointestinal diseases: potential therapeutic applications.” *Expert Opin Investig Drugs*. 2003 Jan;12(1):39-49. Accessed Dec 28, 2013: <http://www.ncbi.nlm.nih.gov/pubmed/12517253>.

36 UC San Diego Health System (2012). “Smoked Cannabis Reduced Some Symptoms of Multiple Sclerosis.” *News Release;* May 14, 2012. Accessed Dec 21, 2013: <http://health.ucsd.edu/news/releases/Pages/2012-05-14-smoked-cannabis-reduces-symptoms-of-multiple-sclerosis.aspx>.

37 Ashton CH et al (2005). “Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.” *Journal of Psychopharmacology*: 2005 May;19(3):293-300. Accessed Dec 10, 2013: <http://www.ncbi.nlm.nih.gov/pubmed/15888515>.

38 Zimm, A (2007). “Marijuana Stops Growth of Lung Cancer Tumors in Mice.” *Bloomberg*. 2007 Apr 17. Accessed Jan 6, 2014: <http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aLRKiCeoXoRQ>.

39 Sanchez, C et al (1998). “Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells.” *FEBS Letters*. 1998 Sep 25. Accessed Mar 28, 2013: <http://scholar.qsensei.com/content/y05d9>.

## 40 Guzman, M et al (2006). “A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.” *British Journal of Cancer*: 2006 Jun 27;95, 197-203. Accessed Mar 28, 2013: http://www.nature.com/bjc/journal/v95/n2/abs/6603236a.html.

41 Gallily, R et al (2003). “γ-Irradiation Enhances Apoptosis Induced by Cannabidiol, a Non-psychotropic Cannabinoid, in Cultured HL-60 Myeloblastic Leukemia Cells.” *Leukemia & Lymphoma*: 2001 Jan 1:44(10) 1767-1773. Accessed Mar 28, 2013: <http://informahealthcare.com/doi/abs/10.1080/1042819031000103917>.

42 Hampson, A et al (2003). U.S. Health Patent Office, US6630507 – (B1): *Cannabinoids as antioxidants and neuroprotectants*. 2003 Oct 2007. Accessed Dec 30, 2013: <http://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=6630507&KC=&FT=E&locale=en_EP>.

43 Yazulla, S (2008). “Endocannabinoids in the retina: from marijuana to neuroprotection.” *Prog Retin Eye Res*: 2008 Sept;27(5):501-26. Accessed Dec 21, 2013: <http://www.ncbi.nlm.nih.gov/pubmed/18725316>.

44 Hall, W et al (1995) “A Comparative Appraisal of the Health and Psychological Consequences of Alcohol, Cannabis, Nicotine and Opiate Use.” Accessed February 23, 2013: http://www.druglibrary.org/shaffer/hemp/general/who-index.htm.

45 Joy, J et al (1999) “Marijuana and Medicine: Assessing the Science Base,” Division of Neuroscience and Behavioral Research, Institute of Medicine. Washington, DC: National Academy Press, 1999. pp 3, 83-108. Accessed February 23, 2013: <http://www.nap.edu/openbook.php?isbn=03090715508&page=109>.

46 Casteneada, et al (1991). “THC does not affect striatal dopamine release: microdialysis in freely moving rats”. [Pharmacol Biochem Behav.](http://www.ncbi.nlm.nih.gov/pubmed/1725460) 1991 Nov;40(3):587-91. Accessed February 23, 2013: http://www.ncbi.nlm.nih.gov/pubmed/1725460.

47 Gifford, et al (1997). “The effects of intravenous administration of delta-9-tetrahydrocannabinol on the activity of the A 10 dopamine neurons recorded in vivo in anesthetized rates.” *Neuropsychopharmacology*: 1997. 36(2) pp 96-99. Accessed February 23, 2013: http://www.karger.com/Article/Pdf/119369.

48 New Scientist. “Special Report on Marijuana”. Feb 21, 1998: <http://cifas.us/sites.cifas.drupalgardens.com/files/Newscientist3/pdf>.

49 Melamede, R (2005). “Cannabis and tobacco smoke are not equally carcinogenic.” *Harm Reduction Journal* 2005, Oct 18. Accessed February 23, 2013: <http://www.harmreductionjournal.com/content/2/1/21>.

50 Sidney, S et al (1997) “Marijuana use and cancer incidence.” *Cancer Causes Control*. 1997 Sept;8(5):722-8. Accessed February 23, 2013: <http://www.ncbi.nlm.nih.gov/pubmed/9328194>.

51 James, John S (1997). “Medical marijuana: Unpublished federal study found THC treated rates lived longer, had fewer cancers.” *AIDS Treatment News* 1997, Jan 17. Accessed February 23, 2013: <http://www.thebody.com/content/art31497.html#medmar>.

52 D’Souza G, et al. “Marijuana use is not associated with cervical human papillomavirus natural history or cervical neoplasia in HIV-seropositive or HIV-seronegative women.**”** *Epidemiol Biomarkes Prev.* 2010 Mar; 19(3) 869-72. Accessed February 23, 2013:<http://www.ncbi.nlm.nih.gov/pubmed/20160270>.

53 Polen, et al (1993) . “Health care use by frequent marijuana smokers who do not smoke tobacco.” *West J Med*; 158: pp 596-601. Accessed February 21, 2013: <http://oade.nd.edu/educate-yourself-drugs/marijuana-or-cannabis-sativa/marijuana-manual/myths-and-current-research/>.

54 Gagnon, L. (1994) “Marijuana Less Harmful to Lungs than Cigarettes.” *Medical Post (Quebec)*; 1994, Sep 6. Accessed February 18, 2013: <http://www.erowid.org/plants/cannabis/cannabis_health1.shtml>.

55 Tashkin, et al (1990). “Effects of habitual use of marijuana and/or cocaine on the lung.” *NIDA Res Monogr*. 1990;99: pp 63-67. Accessed February 20, 2013: <http://www.ncbi.nlm.nih.gov/pubmed/2267014>.

56 Tashkin, et al (1997). “Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age.” *AM J Respir Crit Care Med*. 1997;155: pp 141-148. Accessed February 23, 2013: <http://www.atsjournals.org/doi/abs/10.1164/ajrccm.155.1.9001303#.UvVh-EKwI88>. Not sure but think this should probably be Am J

57 US National Academy of Science (1992). “The health and psychological consequences of cannabis use.” *National Drug Strategy Monograph* *(Australia)*. 25. Accessed February 23, 2013: <http://druglibrary.org/schaffer/hemp/medical/home.htm>.

58 Hollister, L. (1986). “Health Aspects of Marijuana.” *Pharmacological Review*. 1996;38(1). Accessed February 18, 2013: <http://druglibrary.org/schaffer/hemp/medical/hollisterhealth.htm>.

59 Stirling, et al (2005). “Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up.” *Schizophrenia Research*. 2005, Jun 1;75(1):pp135-137. Accessed February 20, 2013: <http://www.schres-journal.com/article/S0920-9964(04)00398-6/abstract>.

60 Lyketsos, et al (1999). “Cannabis use and cognitive decline in persons under 65 years of age.” *American Journal of Epidemiology*. 1999, May 1;149:pp794-800. Accessed February 21, 2013: <http://aje.oxfordjournals.org/content/149/9/794.full.pdf>.

61 Sidney, et al (1997). “Marijuana use and mortality.” *Am J Public Health*. 1997 April; 87(4): pp585-590. Accessed January 29, 2013: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1380837/>.

62 Substance Abuse and Mental Health Services Administration (2014) “Cannabis”. Accessed November 27, 2015: http://www.samhsa.gov/atod/cannabis.

63 U.S. Department of Veterans Affairs (2013). “FAQ: How often is treatment successful?” 2013, July 24. Accessed November 23, 2015: <http://www.hepatitis.va.gov/patient/faqs/treatment-success.asp>.

64 Poordad F, et al. (2011). Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine, 364(13): 1195-1206. Accessed November 23, 2015: http://www.webmd.com/hepatitis/combination-antiviral-therapy-for-hepatitis-c#uf1619.

65 Mailman RB, Murthy V (2010) “Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?” Curr Pharm Des 2010;16(5):488-501. Accessed November 27, 2015: <http://www.ncbi.nlm.nih.gov/pubmed/19909227>.

66 Ellis JM (2005). “Cholinesterase inhibitors in the treatment of dementia.” J Am Osteopath Assoc. 2005 Mar;105(3):145-58. Accessed November 27, 2015: <http://www.ncbi.nlm.nih.gov/pubmed/15863734>.

67 McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003154. DOI: 10.1002/14651858.CD003154.pub5.

68 Edney, Anna (2014). “Marijuana Considered for Looser Restrictions by U.S. FDA.” Bloomberg Business, June 20, 2014. Accessed November 27, 2015: http://www.bloomberg.com/news/articles/2014-06-20/drug-regulators-study-easing-u-s-marijuana-restrictions.

**Selected Bibliography**

Adams, Michael P., Dianne L. Josephson, Leland N. Holland. Pharmacology for Nurses, A Pathophysiologic Approach*.* Upper Saddle River, NJ: Pearson Education, Inc. 2005.

Berkow, R, ed The Merck Manual of Diagnosis and Therapy, 15th Edition. Rahway, NJ: Merck Sharp and Dohme Research Laboratories, 1987.

Clough, Walter S.The Human Body, Its Function in Health and Disease, International Claim Association, 1983.

Lehne, Richard A. Pharmacology for Nursing Care, 4th ed*.*, Philadelphia: W.B. Saunders Company, 2001.

Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, 6th ed*.* Philadelphia: W.B. Saunders Company, 1997.